PicoCELA Inc. (NASDAQ: PCLA) has one of the most lopsided supply structures on a U.S. exchange: just 493,026 American Depositary Shares are freely tradeable, while a single counterparty holds 20,000,000 Class A Preferred Shares convertible into common stock at a ratio of one-for-one. That preferred block is roughly 40 times the entire float.

ShareStructure assigns PCLA a dilution risk grade of 6 out of 10 — Elevated.

Why the float is so small

PicoCELA is a Japanese joint-stock company. Its common shares exist on a Japanese share register; only shares deposited with Citibank N.A. and issued as ADSs actually trade on Nasdaq. Of 9,613,805 common shares outstanding, insiders hold 8,553,131, another roughly 567,648 sit with Japanese holders who have never deposited them as ADSs, and the remaining 493,026 — 5.13% of shares outstanding — constitute the entire tradeable supply. The company itself discloses this exact figure in its FY2025 annual report.

The preferred overhang

In July 2026, Singapore-based About Investment Pte. Ltd. purchased 20,000,000 Class A Preferred Shares at $0.25 each, paying $5 million in a private placement. Each preferred share converts into one common share at the holder's discretion. The position is deeply in the money.

There is a ratchet. If the ADS closes at or below $0.50 for 20 consecutive trading days, the conversion ratio doubles to two-for-one, creating 40,000,000 potential common shares — a price-contingent variable conversion feature, meaning that a sustained decline in the stock mechanically manufactures additional supply.

For now, none of this can reach the market. The shares are unregistered restricted securities held by a majority affiliate. Rule 144 — the SEC rule governing resale of restricted stock — imposes a six-month holding period that does not expire until January 16, 2027, after which affiliate volume caps limit sales to approximately 96,138 shares per 90-day window. No resale registration statement is on file. The filing of an F-1 or S-1 covering these shares would be the single most consequential supply event to watch for.

What the structure does — and does not — contain

The conventional toxic vectors are absent. PCLA carries zero warrants outstanding. The only warrant ever contemplated — a 716,146-share instrument with a $0.01 strike intended for a consulting firm — was voted down by shareholders in November 2024. There are no convertible notes, no at-the-market offering facility — a program that lets a company sell shares directly into the open market on an ongoing basis — no equity line of credit, and no active shelf registration — a pre-filed SEC document that allows future stock sales without a new registration.

That absence is what holds the dilution grade at 6 rather than something higher. There is no active drip feeding shares into the float today.

Structural fragilities

Three channels could expand the float without a new SEC filing. First, approximately 567,648 unrestricted common shares held by Japanese investors — including Nikken Lease Kogyo, whose 12-month resale restriction has now lapsed — can be deposited with the ADS depositary at any time to mint new tradeable shares. That alone would more than double the float.

Second, 7,126,667 insider compensation shares carry 20-year transfer restrictions, but both agreements state the prohibition "may be canceled by a resolution of the Company's board of directors." The board's composition is now determined by the controlling preferred holder.

Third, as a foreign private issuer following Japanese home-country corporate governance, PicoCELA is exempt from Nasdaq Listing Rule 5635 — the rule that ordinarily requires shareholder approval before issuing stock exceeding 20% of shares outstanding. The July preferred placement, which conveyed 208% of outstanding shares and transferred voting control, proceeded without any U.S.-side approval gate.

Shares outstanding have grown 733% over the trailing twelve months on a split-adjusted basis, and the placement agent on the preferred deal, Univest Securities, holds an 18-month right of first refusal on all future offerings running through January 2028.